text: <unk>  is a bradykinin B2 receptor antagonist that is FDA approved for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.   Common adverse reactions include pyrexia, transaminase increase, dizziness, and rash.
option_0: Icatibant
option_1: Suvorexant
option_2: Tasimelteon
option_3: Atogepant
option_4: Toremifene
option_5: Vigabatrin
option_6: Fosaprepitant
option_7: Stiripentol